Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hikma partners with Perrigo

Executive Summary

Hikma will market a range of Perrigo consumer healthcare products in the Middle East and North Africa (MENA) region after signing a licensing and distribution agreement with Perrigo’s Omega Pharma OTC affiliate. Under the terms of the deal, Hikma will have the “exclusive right to licence and distribute more than 30 consumer healthcare products – including Davitamon, Prevalin, XLS Medical, Dermalex and Paranix–in all its MENA markets, with the exception of current arrangements in place”.

You may also be interested in...



Hikma Plans to Partner Away From Branded Generics Focus In MENA

With local competitors in the MENA region increasingly able to compete on branded generics, Jordan’s Hikma is shifting the focus of its local operation towards partnering for patent-protected products.

CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year

A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.

HBW US Market News: FTC Returns 'Free Trial' Losses, Old Spice Targets 'Meat Sweats,' More

FTC returns more than $5.4m to more than 100,000 consumers from "free trial" scam;" Hood College names Nutrition Science Program's founding director; Cremer introduces gummy-counting machine; Herbalife renovates LA headquarters; Arby's and Old Spice team up to fight "meat sweats."

Topics

Latest News
UsernamePublicRestriction

Register

GB000932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel